Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-inferiority study of switching from TDF to Vemlino vs Vemlidy in chronic hepatitis B
KCT0011854Phase 4Completed
- Sponsor
- Samil Pharmaceutical Co., Ltd.
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of tenofovir alafenamide in Chronic Hepatitis B (CHB) (2 arms), sponsored by Samil Pharmaceutical Co., Ltd. Started Sep 2023; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on KCT0011854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011854.